Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast

Alexandre de Nonneville, Camille Jauffret, Anthony Gonçalvès, Jean‐Marc Classe, Monique Cohen, Fabien Reyal, Chafika Mazouni, M.-p. Chauvet, Nicolás Chopin, P.-e. Colombo, Eva Jouve, Émile Daraï, Roman Rouzier, Charles Coutant, Pierre Gimbergues, A.-s. Azuar, C. Tunon de Lara, Éric Lambaudie, Gilles HouvenaeghelAnnals 2018 · DOI

Abstract

Background: Invasive lobular carcinoma (ILC) is the second most common histologic breast cancer subtype and represent approximately 10% of all breast cancers. Despite this high frequency, benefit of adjuvant chemotherapy (CT) in ILC is still unclear. Methods: Our objective was to investigate the impact of CT on survival in ILC. Patients were retrospectively identified from a cohort of 23,537 patients who underwent primary surgery in 18 French centres between 1990 and 2014. Only ILC, hormone-positive, HER2-negative patients who received adjuvant endocrine therapy (ET) were included. Endpoints were disease-free survival (DFS) and overall survival (OS). A propensity score for receiving CT was estimated using a logistic regression including age, tumour size, nodal status, lymphovascular invasion (LVI), grade, type of surgery, period and CT. Results: Of a total of 2,318 patients with ILC, 1,485 patients (64%) received ET alone and 823 (36%) received ET+CT. Patients receiving ET+CT had more adverse prognostic features, such as young age, larger tumour size, high grade, macroscopic lymph-node involvement and LVI, received more adjuvant radiotherapy and underwent more often mastectomy. In a multivariate Cox model, we observed a beneficial effect of addition of CT to ET on both DFS and OS, (HR = 0.61, 95% CI [0.41-0.90]; p = 0.01 and 0.52, 95% CI [0.31-0.87]; p = 0.01, respectively). This effect was even more pronounced when propensity score-matching, aiming to compensate for baseline characteristics, was used. Ten-year estimates DFS in case-matched patients for propensity score analysis were 90% (95% CI [87%-93.4%]) in the ET+CT group vs. 66% (95% CI [61.4%-71.4%]) with ET alone and 10-year estimates OS were 96% (95% CI [93.8%-98%]) in the ET+CT group vs. 71% (95% CI [66.6% et 76.2%]) with ET alone. Regarding subgroup analysis, low-risk patients without CT did not have significant differences in DFS or OS compared to low-risk patients with CT. Conclusions: Patients receiving adjuvant ET for hormone receptor-positive, HER2-negative ILC could derive significant DFS and OS benefits from CT. Our results highlight that patients with high-risk ILC should not be denied adjuvant CT because of such histologic subtype. Legal entity responsible for the study: Gilles Houvenaeghel. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
BibTeX
@article{nonneville2018benefit,
  author = {Alexandre de Nonneville and Camille Jauffret and Anthony Gonçalvès and Jean‐Marc Classe and Monique Cohen and Fabien Reyal and Chafika Mazouni and M.-P. Chauvet and Nicolás Chopin and P.-E. Colombo and Eva Jouve and Émile Daraï and Roman Rouzier and Charles Coutant and Pierre Gimbergues and A.-S. Azuar and C. Tunon de Lara and Éric Lambaudie and Gilles Houvenaeghel},
  title = {{Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast}},
  journal = {Annals},
  year = {2018},
  doi = {10.1093/annonc/mdy270.190},
}

Loading related content...

Figure